Maxim stopped a Kaufempfehlung “Halten” for Aethlon Medical-Aktien trotz clinical Fortschritte fest from Investing.com

The Donnerstag labels the Maxim Group as “Halten”-kaufempfehlung for the Aktien von Aethlon Medical (NASDAQ:AEMD), a new Kursziel festival. Aethlon Medical has a thorough brand assessment in clinical clinical studies.

If this study takes place, the first two patients can be investigated in a clinical trial, while the hemopurifier is investigated in Krebs patients. These patients are discussed more solidly with anti-PD-1 therapy with Keytruda or opdivo.

The study, which is focused on Security, during the study and the research concentration, has its Reichsweiter-weitert. Two patients in Australia are now available for patients. It is possible that there is an Australian base and one of the institutions that established the Ethics Commission. There is a statement for Aethlon Medical’s Clinical Research studies there.

The Maxim Group has completed the results of the study until the end of March 2025. These are the first dates of T-Zellen and additional vesicles until the end of September 2025. These data points are separated from each other, one of the advantages of hemopurifiers in the sick population.

Aethlon Medical’s oncology team has explored the possibilities of hemopurifiers in other medical studies. The research that is done in practice has done a lot of research into the reduction of complications after organ transplantation, reimburses the Viren and Exosomes from the graft organs organization. In August 2024, the positive results of the investigation into the patient’s health were reversed.

Proud that the Entwicklungen has done by the Maxim Group, is the Road to the Kommerzialisierung of the Hemopurifiers of Aethlon Medical, nor uncertain. The Kaufempfehlung “Halten” reflects this Vorsicht more broadly, while the Unternehmen weiterhin the notnauwen clinical and regulatory Prozesse duchläuft, a product to bring to the market.

In other cases, Aethlon Medical has authorized more brand information. James B. Frakes became permanent Chief Executive Officer and was appointed Chief Operating Officer by Guy F. Cipriani. We are proud of our net income of 2.6 million US dollars in the first quarter of 2025. Aethlon Medical will receive a salary of 9.1 million US dollars.

The Unternehmen have an Aktienoptionsplan with 3 Millionen Aktien, a talent that develops and stops. Aethlon Medical has provided the generic care, the American generic company has reached a number of 3 million people.

Aethlon Medical’s Hemopurifier device has completed the Medanta Institutional Ethics Committee’s full ethical review for a clinical trial in India. This research has led to patient recruitment at the Royal Adelaide Hospital for a clinical trial of haemopurifiers in patients with solid tumours.

Darüber has investigated the hemopurifier in one of the clinical studies, which could explain the problem with kidney transplants. Dies as the young Entwicklungen at Aethlon Medical.

InvestingPro Acknowledgment

Aethlon Medical’s young Fortschritte in clinical trials follows the financial background reforms, with the data from InvestingPro. The market capitalization of the single market entered a modest amount of US$5.66 million and the investors’ vision was reflected more broadly. It is a matter of a while with the “Halten” of the Maxim Group and the unhealthy path to the commercial development of the article.

InvestingPro-Tipps have ensured that Aethlon Medical “burns fast Bargeld” and “doesn’t have a profitable war in the last month of the month”. These factors underline the financial risks that began with the clinical trial and guidance of internal medicine. Since the second term has “more money as debt in the blessing of Bilanz hält”, there is a certain beruhigung, but I think the high bargeldvernnungsspeed will be weighed.

The corporate war is managed by InvestingPro data a trend of -75.46% over one year. This mirror is a mirror for the active market research that broadens Aethlon Medical’s prospects, with the potential blessing of Hemopurifier Technology.

Before you do any of the following analysis, give InvestingPro 11 other tips for Aethlon Medical, one of the many financial advantages and market positions of our third-party companies.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.